Moreover, galunisertib 35 triggers the pyroptotic pathway in glioblastoma, pancreatic cancer, and hepatocellular carcinoma through caspase-1/GSDMD activation [137, 138]. The gene discussed is CASP1; the disease is pancreatic neoplasm.